MESOBLAST LIMITED - Announcements

0.00%

$2.29

Market Cap $2.931B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

MSB	Material Announcement	PRICE SENSITIVE	05/12/24	112.64KB	Share
MSB	Pause in Trade	PRICE SENSITIVE	05/12/24	115.3KB	Share
MSB	FDA Grants Mesoblast RMAT Designation	PRICE SENSITIVE	05/12/24	196.86KB	Share
MSB	REVASCOR Improves Survival & Reduces Major Morbidity		03/12/24	205.8KB	Share
MSB	Becoming a substantial holder		21/11/24	1.87MB	Share
MSB	Results of Meeting		15/11/24	251.44KB	Share
MSB	Final Director's Interest Notice		15/11/24	265.82KB	Share
MSB	CEO Presentation to 2024 Annual General Meeting		15/11/24	2.24MB	Share
MSB	Mesoblast Chair Message to 2024 AGM		15/11/24	177.51KB	Share
MSB	Response to ASX Price Query	PRICE SENSITIVE	14/11/24	364.45KB	Share
MSB	Notification regarding unquoted securities - MSB		12/11/24	17.57KB	Share
MSB	Warrant Prospectus Related to Convertible Note Agreement		07/11/24	560.06KB	Share
MSB	Ceasing to be a substantial holder		05/11/24	1.22MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	441.54KB	Share
MSB	Annual Report to Shareholders		17/10/24	4.25MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		17/10/24	414.34KB	Share
MSB	Appendix 4G and Corporate Governance Statement		17/10/24	468.83KB	Share
MSB	Notification of cessation of securities - MSB		11/10/24	12.74KB	Share
MSB	Notification regarding unquoted securities - MSB		11/10/24	16.21KB	Share
MSB	Change in substantial holding		10/10/24	235.74KB	Share
MSB	Becoming a substantial holder		09/10/24	1.01MB	Share
MSB	Proposed issue of securities - MSB		30/09/24	16.48KB	Share
MSB	Mesoblast Option to Issue up to US$50m Convertible Notes	PRICE SENSITIVE	30/09/24	193.91KB	Share
MSB	Ceasing to be a substantial holder		27/09/24	1.44MB	Share
MSB	Becoming a substantial holder		17/09/24	1.07MB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	29/08/24	548.01KB	Share
MSB	Annual Financial Results Presentation	PRICE SENSITIVE	29/08/24	2.38MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	29/08/24	2.53MB	Share
MSB	Mesoblast 2024 Full Year Financial Results Webcast		28/08/24	114.37KB	Share
MSB	Class Action Resolution	PRICE SENSITIVE	21/08/24	128.66KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	432.15KB	Share
MSB	FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L	PRICE SENSITIVE	23/07/24	185.89KB	Share
MSB	Confirmatory Phase 3 Back Pain Trial Actively Enrols		22/07/24	151.13KB	Share
MSB	Appendix 3Y for Philip Krause		12/07/24	198.24KB	Share
MSB	Notification regarding unquoted securities - MSB		12/07/24	16.26KB	Share
MSB	Notification of cessation of securities - MSB		12/07/24	12.8KB	Share
MSB	Change in substantial holding		12/07/24	147.76KB	Share
MSB	Mesoblast Resubmits BLA with FDA for Ryoncil Approval	PRICE SENSITIVE	09/07/24	178.36KB	Share
MSB	Mesoblast to File BLA for Ryoncil FDA Approval Next Week		01/07/24	157.33KB	Share
MSB	Mesoblast Corporate Presentation at Investor Conference		03/06/24	157.16KB	Share
MSB	Corporate Presentation		03/06/24	1.62MB	Share
MSB	Appendix 3Y for Eric Rose		10/05/24	215.42KB	Share
MSB	Appendix 3Y for Eric Rose		03/05/24	215.34KB	Share
MSB	Change in substantial holding		02/05/24	127.29KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	416.56KB	Share
MSB	Mesoblast Chair Transition		30/04/24	131.25KB	Share
MSB	Appendix 3Y for Jane Bell		16/04/24	171.94KB	Share
MSB	Application for quotation of securities - MSB		16/04/24	17.59KB	Share
MSB	Notification regarding unquoted securities - MSB		16/04/24	15.92KB	Share
MSB	Notification of cessation of securities - MSB		15/04/24	12.8KB	Share
MSB	Change in substantial holding		09/04/24	2.01MB	Share
MSB	Change in substantial holding		02/04/24	1.06MB	Share
MSB	FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA	PRICE SENSITIVE	26/03/24	159.39KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	26/03/24	114KB	Share
MSB	Cleansing Notice		26/03/24	108.36KB	Share
MSB	Application for quotation of securities - MSB		22/03/24	14.19KB	Share
MSB	Change in substantial holding		20/03/24	1.37MB	Share
MSB	Proposed issue of securities - MSB		20/03/24	14.8KB	Share
MSB	Cleansing Notice		19/03/24	227.96KB	Share
MSB	Appendix 2A		18/03/24	344.46KB	Share
MSB	Proposed issue of securities - MSB		14/03/24	15.09KB	Share
MSB	Mesoblast Completes Placement and Entitlement Offer	PRICE SENSITIVE	14/03/24	159.66KB	Share
MSB	FDA Supports Accelerated Approval Pathway for Heart Failure	PRICE SENSITIVE	11/03/24	183.32KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	29/02/24	486.32KB	Share
MSB	Half Year Financial Results Presentation	PRICE SENSITIVE	29/02/24	1.7MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	29/02/24	1.66MB	Share
MSB	Mesoblast 2024 Half Year Financial Results Webcast		26/02/24	113.58KB	Share
MSB	FDA Grants Orphan Drug Designation for Revascor	PRICE SENSITIVE	15/02/24	176.6KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	423.11KB	Share
MSB	FDA Grants Rare Pediatric Disease Designation for Revascor	PRICE SENSITIVE	19/01/24	181.5KB	Share
MSB	App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina		15/01/24	339.51KB	Share
MSB	Notification regarding unquoted securities - MSB		15/01/24	27.4KB	Share
MSB	Notification of cessation of securities - MSB		15/01/24	23.21KB	Share
MSB	Appendix 3Y for Joseph Swedish		03/01/24	213.56KB	Share
MSB	Amended Appendix 3Gs for Unquoted Warrants		03/01/24	814.1KB	Share
MSB	Update on Institutional Placement and Entitlement Offer		28/12/23	139.29KB	Share
MSB	Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina		28/12/23	525.98KB	Share
MSB	Appendix 2A		28/12/23	347.15KB	Share
MSB	Notification of cessation of securities - MSB		28/12/23	21.55KB	Share
MSB	Change of Director's Interest Notice - Silviu Itescu		12/12/23	199.23KB	Share
MSB	Institutional Placement Cleansing Notice		12/12/23	263.86KB	Share
MSB	Appendix 2A		11/12/23	375.53KB	Share
MSB	Information For Retail Shareholders	PRICE SENSITIVE	08/12/23	2.54MB	Share
MSB	Mesoblast Completes Institutional Allocation	PRICE SENSITIVE	05/12/23	197.91KB	Share
MSB	Entitlement Offer Cleansing Notice		04/12/23	168.57KB	Share
MSB	Appendix 3B Entitlement Offer and Placement		04/12/23	694.03KB	Share
MSB	Entitlement Offer and Placement Investor Presentation	PRICE SENSITIVE	04/12/23	2.06MB	Share
MSB	MSB Launches Entitlement Offer and Placement	PRICE SENSITIVE	04/12/23	292.56KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/12/23	217.16KB	Share
MSB	Amended Constitution		29/11/23	915.58KB	Share
MSB	Results of Meeting		28/11/23	187.13KB	Share
MSB	CEO Presentation to 2023 Annual General Meeting		28/11/23	1.89MB	Share
MSB	Mesoblast Chairman Message to 2023 AGM		28/11/23	181.09KB	Share
MSB	MSB Files for FDA Designations in Congenital Heart Disease		27/11/23	191.4KB	Share
MSB	Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial		22/11/23	174.07KB	Share
MSB	Mesoblast Corporate Presentation		15/11/23	1.68MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	398.85KB	Share
MSB	Annual Report to Shareholders		30/10/23	3.92MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		30/10/23	471.69KB	Share
MSB	Appendix 4G and Corporate Governance Statement		30/10/23	473.72KB	Share

MSB Material Announcement
05/12/24	PRICE SENSITIVE	112.64KB	Share
MSB Pause in Trade
05/12/24	PRICE SENSITIVE	115.3KB	Share
MSB FDA Grants Mesoblast RMAT Designation
05/12/24	PRICE SENSITIVE	196.86KB	Share
MSB REVASCOR Improves Survival & Reduces Major Morbidity
03/12/24		205.8KB	Share
MSB Becoming a substantial holder
21/11/24		1.87MB	Share
MSB Results of Meeting
15/11/24		251.44KB	Share
MSB Final Director's Interest Notice
15/11/24		265.82KB	Share
MSB CEO Presentation to 2024 Annual General Meeting
15/11/24		2.24MB	Share
MSB Mesoblast Chair Message to 2024 AGM
15/11/24		177.51KB	Share
MSB Response to ASX Price Query
14/11/24	PRICE SENSITIVE	364.45KB	Share
MSB Notification regarding unquoted securities - MSB
12/11/24		17.57KB	Share
MSB Warrant Prospectus Related to Convertible Note Agreement
07/11/24		560.06KB	Share
MSB Ceasing to be a substantial holder
05/11/24		1.22MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	441.54KB	Share
MSB Annual Report to Shareholders
17/10/24		4.25MB	Share
MSB Notice of Annual General Meeting and Proxy Form
17/10/24		414.34KB	Share
MSB Appendix 4G and Corporate Governance Statement
17/10/24		468.83KB	Share
MSB Notification of cessation of securities - MSB
11/10/24		12.74KB	Share
MSB Notification regarding unquoted securities - MSB
11/10/24		16.21KB	Share
MSB Change in substantial holding
10/10/24		235.74KB	Share
MSB Becoming a substantial holder
09/10/24		1.01MB	Share
MSB Proposed issue of securities - MSB
30/09/24		16.48KB	Share
MSB Mesoblast Option to Issue up to US$50m Convertible Notes
30/09/24	PRICE SENSITIVE	193.91KB	Share
MSB Ceasing to be a substantial holder
27/09/24		1.44MB	Share
MSB Becoming a substantial holder
17/09/24		1.07MB	Share
MSB MSB Annual Financial Results and Operational Update
29/08/24	PRICE SENSITIVE	548.01KB	Share
MSB Annual Financial Results Presentation
29/08/24	PRICE SENSITIVE	2.38MB	Share
MSB Preliminary Final Report including Appendix 4E
29/08/24	PRICE SENSITIVE	2.53MB	Share
MSB Mesoblast 2024 Full Year Financial Results Webcast
28/08/24		114.37KB	Share
MSB Class Action Resolution
21/08/24	PRICE SENSITIVE	128.66KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	432.15KB	Share
MSB FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
23/07/24	PRICE SENSITIVE	185.89KB	Share
MSB Confirmatory Phase 3 Back Pain Trial Actively Enrols
22/07/24		151.13KB	Share
MSB Appendix 3Y for Philip Krause
12/07/24		198.24KB	Share
MSB Notification regarding unquoted securities - MSB
12/07/24		16.26KB	Share
MSB Notification of cessation of securities - MSB
12/07/24		12.8KB	Share
MSB Change in substantial holding
12/07/24		147.76KB	Share
MSB Mesoblast Resubmits BLA with FDA for Ryoncil Approval
09/07/24	PRICE SENSITIVE	178.36KB	Share
MSB Mesoblast to File BLA for Ryoncil FDA Approval Next Week
01/07/24		157.33KB	Share
MSB Mesoblast Corporate Presentation at Investor Conference
03/06/24		157.16KB	Share
MSB Corporate Presentation
03/06/24		1.62MB	Share
MSB Appendix 3Y for Eric Rose
10/05/24		215.42KB	Share
MSB Appendix 3Y for Eric Rose
03/05/24		215.34KB	Share
MSB Change in substantial holding
02/05/24		127.29KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	416.56KB	Share
MSB Mesoblast Chair Transition
30/04/24		131.25KB	Share
MSB Appendix 3Y for Jane Bell
16/04/24		171.94KB	Share
MSB Application for quotation of securities - MSB
16/04/24		17.59KB	Share
MSB Notification regarding unquoted securities - MSB
16/04/24		15.92KB	Share
MSB Notification of cessation of securities - MSB
15/04/24		12.8KB	Share
MSB Change in substantial holding
09/04/24		2.01MB	Share
MSB Change in substantial holding
02/04/24		1.06MB	Share
MSB FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26/03/24	PRICE SENSITIVE	159.39KB	Share
MSB Pause in Trading
26/03/24	PRICE SENSITIVE	114KB	Share
MSB Cleansing Notice
26/03/24		108.36KB	Share
MSB Application for quotation of securities - MSB
22/03/24		14.19KB	Share
MSB Change in substantial holding
20/03/24		1.37MB	Share
MSB Proposed issue of securities - MSB
20/03/24		14.8KB	Share
MSB Cleansing Notice
19/03/24		227.96KB	Share
MSB Appendix 2A
18/03/24		344.46KB	Share
MSB Proposed issue of securities - MSB
14/03/24		15.09KB	Share
MSB Mesoblast Completes Placement and Entitlement Offer
14/03/24	PRICE SENSITIVE	159.66KB	Share
MSB FDA Supports Accelerated Approval Pathway for Heart Failure
11/03/24	PRICE SENSITIVE	183.32KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
29/02/24	PRICE SENSITIVE	486.32KB	Share
MSB Half Year Financial Results Presentation
29/02/24	PRICE SENSITIVE	1.7MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
29/02/24	PRICE SENSITIVE	1.66MB	Share
MSB Mesoblast 2024 Half Year Financial Results Webcast
26/02/24		113.58KB	Share
MSB FDA Grants Orphan Drug Designation for Revascor
15/02/24	PRICE SENSITIVE	176.6KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	423.11KB	Share
MSB FDA Grants Rare Pediatric Disease Designation for Revascor
19/01/24	PRICE SENSITIVE	181.5KB	Share
MSB App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina
15/01/24		339.51KB	Share
MSB Notification regarding unquoted securities - MSB
15/01/24		27.4KB	Share
MSB Notification of cessation of securities - MSB
15/01/24		23.21KB	Share
MSB Appendix 3Y for Joseph Swedish
03/01/24		213.56KB	Share
MSB Amended Appendix 3Gs for Unquoted Warrants
03/01/24		814.1KB	Share
MSB Update on Institutional Placement and Entitlement Offer
28/12/23		139.29KB	Share
MSB Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina
28/12/23		525.98KB	Share
MSB Appendix 2A
28/12/23		347.15KB	Share
MSB Notification of cessation of securities - MSB
28/12/23		21.55KB	Share
MSB Change of Director's Interest Notice - Silviu Itescu
12/12/23		199.23KB	Share
MSB Institutional Placement Cleansing Notice
12/12/23		263.86KB	Share
MSB Appendix 2A
11/12/23		375.53KB	Share
MSB Information For Retail Shareholders
08/12/23	PRICE SENSITIVE	2.54MB	Share
MSB Mesoblast Completes Institutional Allocation
05/12/23	PRICE SENSITIVE	197.91KB	Share
MSB Entitlement Offer Cleansing Notice
04/12/23		168.57KB	Share
MSB Appendix 3B Entitlement Offer and Placement
04/12/23		694.03KB	Share
MSB Entitlement Offer and Placement Investor Presentation
04/12/23	PRICE SENSITIVE	2.06MB	Share
MSB MSB Launches Entitlement Offer and Placement
04/12/23	PRICE SENSITIVE	292.56KB	Share
MSB Trading Halt
01/12/23	PRICE SENSITIVE	217.16KB	Share
MSB Amended Constitution
29/11/23		915.58KB	Share
MSB Results of Meeting
28/11/23		187.13KB	Share
MSB CEO Presentation to 2023 Annual General Meeting
28/11/23		1.89MB	Share
MSB Mesoblast Chairman Message to 2023 AGM
28/11/23		181.09KB	Share
MSB MSB Files for FDA Designations in Congenital Heart Disease
27/11/23		191.4KB	Share
MSB Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
22/11/23		174.07KB	Share
MSB Mesoblast Corporate Presentation
15/11/23		1.68MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	398.85KB	Share
MSB Annual Report to Shareholders
30/10/23		3.92MB	Share
MSB Notice of Annual General Meeting and Proxy Form
30/10/23		471.69KB	Share
MSB Appendix 4G and Corporate Governance Statement
30/10/23		473.72KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.29		Change 0.000(0.00%)		Mkt cap ! $2.931B

Open	High	Low	Value	Volume
$2.26	$2.31	$2.25	$4.493M	1.965M

Buyers (Bids)

No.	Vol.	Price($)
1	13044	$2.28

Sellers (Offers)

Price($)	Vol.	No.
$2.29	4885	3

View Market Depth

No.	Vol.	Price($)
1	13044	2.280
5	56371	2.270
7	81639	2.260
26	130952	2.250
10	21431	2.240

Price($)	Vol.	No.
2.290	4885	3
2.300	59567	4
2.310	15489	4
2.320	50600	3
2.330	23472	4

Last trade - 16.14pm 12/08/2025 (20 minute delay)


Last $2.28		Change 0.000 ( 0.33 %)
Open	High	Low	Volume
$2.27	$2.31	$2.26	689025
Last updated 15.59pm 12/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories